Orgenesis Inc. Capital expenditures

Capital expenditures of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.

Highlights and Quick Summary

  • Capital expenditures for the quarter ending September 29, 2021 was $-1.82 Million (a 79.64% increase compared to previous quarter)
  • Year-over-year quarterly Capital expenditures increased by 690.43%
  • Annual Capital expenditures for 2020 was $-1.52 Million (a -87.4% decrease from previous year)
  • Annual Capital expenditures for 2019 was $-12.1 Million (a 97.83% increase from previous year)
  • Annual Capital expenditures for 2018 was $-6.09 Million (a 9.63% increase from previous year)
  • Twelve month Capital expenditures ending September 29, 2021 was $-3.59 Million (a 71.77% increase compared to previous quarter)
  • Twelve month trailing Capital expenditures increased by 136.5% year-over-year
Trailing Capital expenditures for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-3.59 Million $-2.09 Million $-1.35 Million $-1.52 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of Orgenesis Inc.

Most recent Capital expendituresof ORGS including historical data for past 10 years.

Interactive Chart of Capital expenditures of Orgenesis Inc.

Orgenesis Inc. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-1.82 $-1.01 $-0.53
2020 $-0.23 $-0.32 $-0.27 $-0.7 $-1.52
2019 $-6.01 $-3.32 $-1.77 $-0.96 $-12.05
2018 $-1.66 $-1.8 $-2.08 $-0.55 $-6.09
2017 $-0.17 $-0.21 $-0.23 $-0.23 $-0.98
2016 $-0.33 $-0.34 $-0.7 $-0.71 $-1.43
2015 $-0.98 $-0.98
2014 $-0.0 $-0.01
2013 $0.0 $-0.01
2012 $0.0 $0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.